Comparative study of regulatory authorities across countries is vital for B.Pharm students to understand global drug regulation, pharmacovigilance, GMP, clinical trial approval, and marketing authorization processes. This topic compares agencies such as FDA (USA), EMA (EU), MHRA (UK), CDSCO (India), PMDA (Japan) and others, exploring dossier requirements, ICH guidelines, eCTD submissions, inspection systems, and post-marketing surveillance. Knowing differences in regulatory pathways—new drug applications, generics, biosimilars, emergency use authorizations, and harmonization efforts like mutual recognition and reliance—prepares students for careers in regulatory affairs, quality assurance, and clinical research. It emphasizes practical examples, case studies, and comparative timelines to deepen conceptual understanding. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. Which regulatory authority coordinates the Centralised Marketing Authorisation procedure for medicines valid across all EU member states?
- Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- Central Drugs Standard Control Organisation (CDSCO)
- Pharmaceuticals and Medical Devices Agency (PMDA)
Correct Answer: European Medicines Agency (EMA)
Q2. Which document contains the Common Technical Document (CTD) format used for regulatory submissions internationally?
- WHO Technical Report Series
- ICH M4
- PIC/S Guide
- US CFR Title 21
Correct Answer: ICH M4
Q3. Which authority is primarily responsible for approving Investigational New Drug (IND) applications in the United States?
- EMA
- MHRA
- FDA
- CDSCO
Correct Answer: FDA
Q4. Which international initiative aims to harmonize technical requirements for pharmaceuticals among major regulatory agencies?
- Mutual Recognition Agreement (MRA)
- International Council for Harmonisation (ICH)
- PIC/S Inspections Program
- WHO Prequalification Programme
Correct Answer: International Council for Harmonisation (ICH)
Q5. Which database is used by the WHO for global pharmacovigilance signal detection?
- VAERS
- EudraVigilance
- VigiBase
- FAERS
Correct Answer: VigiBase
Q6. What is the main focus of PIC/S (Pharmaceutical Inspection Co-operation Scheme)?
- Clinical trial design harmonization
- Good Manufacturing Practice (GMP) inspection convergence
- Marketing authorization evaluations
- Pharmacovigilance database management
Correct Answer: Good Manufacturing Practice (GMP) inspection convergence
Q7. Which regulator introduced the Emergency Use Authorization (EUA) pathway widely referenced during public health emergencies?
- PMDA (Japan)
- EMA (EU)
- FDA (USA)
- CDSCO (India)
Correct Answer: FDA (USA)
Q8. In India, which body is the central regulator for approval of clinical trials and marketing authorizations?
- Central Drugs Standard Control Organisation (CDSCO)
- Food Safety and Standards Authority of India (FSSAI)
- Indian Council of Medical Research (ICMR)
- National Pharmaceuticals Authority (NPA)
Correct Answer: Central Drugs Standard Control Organisation (CDSCO)
Q9. Which guideline series covers pharmacovigilance and safety reporting in ICH nomenclature?
- ICH Q-series
- ICH E-series
- ICH S-series
- ICH E2-series
Correct Answer: ICH E2-series
Q10. Which regulatory agency publishes the Electronic Common Technical Document (eCTD) specifications used for electronic submissions?
- World Health Organization (WHO)
- FDA, EMA and PMDA collaboratively through ICH
- Only FDA
- Only EMA
Correct Answer: FDA, EMA and PMDA collaboratively through ICH
Q11. Which procedure permits a marketing authorisation holder to recognize an approval granted by another country under defined conditions?
- Centralised Procedure
- Mutual Recognition Procedure / Reliance
- Decentralised Clinical Trial
- Priority Review Program
Correct Answer: Mutual Recognition Procedure / Reliance
Q12. Which agency is known for its Conditional Marketing Authorization (CMA) pathway enabling earlier access to medicines in Europe?
- FDA
- EMA
- CDSCO
- TGA (Australia)
Correct Answer: EMA
Q13. Which of the following is a primary difference between generic drug approval pathways across countries?
- Requirement for full clinical trials for every generic
- Bioequivalence study acceptance and interchangeability criteria
- All countries mandate animal toxicity studies
- Generics never require stability data
Correct Answer: Bioequivalence study acceptance and interchangeability criteria
Q14. Which regulatory concept refers to post-marketing collection and assessment of adverse drug reactions?
- Preclinical evaluation
- Pharmacovigilance
- Good Distribution Practice
- Labeling strategy
Correct Answer: Pharmacovigilance
Q15. Which agency maintains the FAERS database for adverse event reports?
- EMA
- FDA
- WHO
- CDSCO
Correct Answer: FDA
Q16. Which document provides the standard format for stability testing data recommended by ICH?
- ICH Q1A(R2)
- ICH E6(R2)
- ICH M4
- ICH S6
Correct Answer: ICH Q1A(R2)
Q17. Which regulator commonly requires a local clinical trial or bridging studies for novel biologics before local approval?
- FDA (USA)
- All regulators uniformly waive local trials
- Some regulators such as CDSCO may require local data or bridging studies
- EMA requires only in vitro data
Correct Answer: Some regulators such as CDSCO may require local data or bridging studies
Q18. Which regulatory framework addresses Good Clinical Practice requirements internationally?
- ICH E6(R2)
- ICH Q3
- WHO GMP Guide
- ICH M2
Correct Answer: ICH E6(R2)
Q19. Which authority is the national regulator for medicines and medical devices in the United Kingdom after Brexit?
- EMA
- MHRA
- FDA
- PMDA
Correct Answer: MHRA
Q20. Which of the following is a common metric regulators use to prioritise review of marketing applications?
- Therapeutic novelty and unmet medical need
- Advertising budget of sponsor
- Number of sales representatives
- Manufacturing site size only
Correct Answer: Therapeutic novelty and unmet medical need
Q21. Which procedure in the EU allows simultaneous evaluation in several member states when no centralised route applies?
- Centralised Procedure
- Decentralised Procedure (DCP)
- FDA Priority Review
- WHO Prequalification
Correct Answer: Decentralised Procedure (DCP)
Q22. Which regulatory authority is known for rigorous post-marketing inspection programs and maintains EudraGMP?
- CDSCO
- EMA (via EU systems)
- FDA only
- PMDA only
Correct Answer: EMA (via EU systems)
Q23. Which pathway is commonly used for biosimilar approvals and reflects differences in comparability requirements across regulators?
- Full new biological license application without reference product
- Biosimilar application demonstrating analytical, nonclinical and clinical comparability
- Over-the-counter monograph submission
- Traditional generics pathway without clinical data
Correct Answer: Biosimilar application demonstrating analytical, nonclinical and clinical comparability
Q24. Which international body often provides prequalification for medicines to aid regulatory reliance in low- and middle-income countries?
- ICH
- WHO Prequalification Programme
- FDA Orange Book
- EMA Committee for Advanced Therapies (CAT)
Correct Answer: WHO Prequalification Programme
Q25. Which concept describes a regulator accepting data and decisions from another trusted regulator to accelerate approvals?
- Full duplication
- Reliance or recognition
- Decentralisation
- Localisation
Correct Answer: Reliance or recognition
Q26. Which regulatory activity assesses manufacturing facilities for compliance with GMP?
- Clinical trial monitoring
- Regulatory dossier writing
- Inspection / GMP audit
- Pharmacovigilance signal detection
Correct Answer: Inspection / GMP audit
Q27. Which European system is used for reporting suspected adverse reactions to medicines?
- EudraVigilance
- FAERS
- VigiBase
- VAERS
Correct Answer: EudraVigilance
Q28. Which regulatory document outlines quality, safety and efficacy modules for a marketing authorisation dossier?
- Common Technical Document (CTD)
- ICH Q8 only
- Good Distribution Practice (GDP) guide
- Pharmacopoeial monograph
Correct Answer: Common Technical Document (CTD)
Q29. Which regulator is responsible for the approval and post-market surveillance of medical products in Japan?
- PMDA (Pharmaceuticals and Medical Devices Agency)
- FDA
- EMA
- MHRA
Correct Answer: PMDA (Pharmaceuticals and Medical Devices Agency)
Q30. Which practice helps align inspection standards and reduce duplication of regulatory inspections internationally?
- Regulatory isolation
- PIC/S membership and mutual inspection cooperation
- Duplicate national audits without sharing
- Unilateral acceptance of self-declarations only
Correct Answer: PIC/S membership and mutual inspection cooperation
